Information Provided By: 
Fly News Breaks for June 18, 2018
RHHBY, PTCT, BIIB
Jun 18, 2018 | 09:13 EDT
While the spinal muscular atrophy data from PTC Therapeutics (PTCT) and Roche (RHHBY) are early, they may add to the ongoing uncertainty about durability of Biogen's (BIIB) Spinraza past 2020, Jefferies analyst Michael Yee tells investors in a research note. The data reinforce a need for more visible Biogen growth drivers, the analyst adds. Yee admits, however, that Biogen "remains inexpensive" and has fairly low expectations. He keeps a Hold rating on the shares with a $300 price target. :theflyonthewal
News For BIIB;PTCT;RHHBY From the Last 2 Days
BIIB
Apr 24, 2024 | 16:14 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
BIIB
Apr 24, 2024 | 13:04 EDT
BIIB
Apr 24, 2024 | 08:50 EDT
Check out this morning's top movers from around Wall Street, compiled by The Fly. UP AFTER EARNINGS... To see the rest of the story go to thefly.com. See Story Here
BIIB
Apr 24, 2024 | 06:50 EDT
BIIB
Apr 24, 2024 | 06:48 EDT
RHHBY
Apr 24, 2024 | 06:33 EDT
RHHBY
Apr 24, 2024 | 06:30 EDT
